Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Discontinuation and Re-initiation of Risperidone Long-Acting Injection in First-Episode Schizophrenia
NCT00378092Phase 4Completed
- Sponsor
- Johnson & Johnson
- Start
- Apr 2006
- Primary completion
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of risperidone in schizophrenia, sponsored by Johnson & Johnson. Started Apr 2006; status: completed.
02
Drugs
risperidone
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT00378092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00378092.